Loading...

SANA SANA BIOTECHNOLOGY INC Management Changes 8-K Filing

SN B

SN

SANA BIOTECHNOLOGY INC

(SANA)

2024 8-K

Show Summary

Summary

Product Expansion

Equity Offerings

Financial Results

Corporate Presentation

Financial Results

Management Changes

Management Change

Earnings Reports

Annual Meeting Results

Financial Results Announcement

Resignation of Executive

Financial Results Announcement

Public Offering

Financial Update

Conference Presentation

Financial Results Announcement

Portfolio Update and Workfo...

Regulation FD Disclosure

Termination of Lease Agreement

Financial Results Announcement

Annual Meeting Results

Presentation at Conference

Earnings Reports

Resignation of Executive

Management Changes

Financial Results Announcement

FDA Clearance for First-in-...

FDA Clearance for First-in-...

Regulation FD Disclosure

External Links:

Nathan Hardy, the Executive Vice President and Chief Financial Officer of Sana Biotechnology, Inc., will resign effective October 4, 2024, for personal reasons, with no disagreements with the company.

AI Assistant

SANA BIOTECHNOLOGY INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.